Global Pharmaceutical Continuous Manufacturing

Global Pharmaceutical Continuous Manufacturing

The global pharmaceutical continuous manufacturing market has undergone substantial growth, primarily fueled by increased demand during the COVID-19 pandemic and reinforced by FDA guidelines supporting biosimilars and generics. Despite facing limited adoption in specific areas such as small molecule oral solid dosage forms and large molecules, the market has consistently demonstrated robust year-on-year growth. Projections indicate that the global pharmaceutical continuous manufacturing market will experience a compound annual growth rate (CAGR) of 16.7% in value terms throughout the forecast period, reaching an estimated value of USD 4,697 million by 2029. This positive trajectory indicates a promising outlook for the integration of CM technology into pharmaceutical operations.

The report also delves into the segmentation of the global pharmaceutical continuous manufacturing market, including outsourced and in-house segments, for the specified period. As Contract Development and Manufacturing Organizations (CDMOs) enhance their capabilities in biomanufacturing, particularly for complex biologic therapies like Cell and Gene Therapies (CGT), pharmaceutical companies are increasingly turning to outsourcing, thus driving the adoption of CM for these therapies, either entirely or in a hybrid format. Tanalyze's estimates project significant growth in the outsourced sector segment, with a forecasted CAGR of 18.8% from 2024 to 2029.

Furthermore, the report analyzes the segmentation of the global pharmaceutical continuous manufacturing market by molecule type for the forecast period. Key segments include large molecules and small molecules. Noteworthy players driving the pharmaceutical Continuous Manufacturing (CM) market include Pfizer, Eli Lilly, and Novartis, particularly in small molecule production, which dominates the CM sector. The small molecules industry held a substantial market share within the global pharmaceutical continuous manufacturing industry in 2023, with an expected growth rate of 13.7% by 2029. This growth is further supported by CDMOs such as Recipharm, SK Biotek, and Patheon, which are heavily investing in CM technology and expanding their capabilities, as evidenced by Almac Group's recent investments in flow chemistry equipment and R&D centers.

The key stakeholders in the pharmaceutical continuous manufacturing market encompass major pharmaceutical players such as Abbott Laboratories, Bayer AG, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Medichem S.A., Novartis AG, Pfizer Inc., Shanghai Pharmaceuticals Holding Co., Ltd., Shionogi & Co., Ltd., and Vertex Pharmaceuticals Incorporated.

Additionally, equipment providers like Applikon Biotechnology B.V. (a part of Getinge Group), Continuus Pharmaceuticals, Inc., Eppendorf AG, GEA Group Aktiengesellschaft, Glatt GmbH, L.B. Bohle Maschinen + Verfahren GmbH, Merck KGaA, Pall Corporation (now part of Danaher Corporation), Syntegon Technology GmbH, and Thermo Fisher Scientific Inc. play crucial roles in supporting the infrastructure and technological requirements of continuous manufacturing.

Furthermore, Contract Development and Manufacturing Organizations (CDMOs) such as Almac Group Limited, Asymchem Laboratories, Inc., Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent Biologics LLC, Corden Pharma International GmbH, Hovione FarmaCiencia SA, Integra CMS (a part of Acumen Pharmaceuticals Inc.), Lonza Group AG, Mycenax Biotech Inc., Seqens SAS, SK Biotek Co., Ltd., and WuXi Biologics (Cayman) Inc. contribute significantly to the development and production capabilities within the pharmaceutical continuous manufacturing sector.

Additionally, process automation players like Avantor, Inc., BiologIC Technologies Ltd., Cytiva Corporation, Innopharma Technology Group Ltd., MicoFluidX Limited, Nucleus Biologics, LLC, Sartorius AG, Siemens AG, Stamm International Corporation, Synthace Limited, Zenith Technologies (a part of Cognizant Technology Solutions Corporation), Aizon Technologies GmbH, Aspen Technology, Inc., Atos SE, Bionet America, Inc., Nexocode LLC, Rockwell Automation, Inc., and Vertica Systems, Inc. contribute to enhancing automation, efficiency, and technological advancements within the pharmaceutical continuous manufacturing landscape. Collectively, these stakeholders play pivotal roles in driving innovation and advancing technologies in continuous manufacturing within the pharmaceutical industry.

This study aims to analyze the global market for various segments of pharmaceutical continuous manufacturing, including:

Purpose: Outsourced and In-house.

Molecule Type: Large Molecules (Drug Product and Drug Substance) and Small Molecules (Finished Dosage Form and Active Pharmaceutical Ingredient).

Region: North America, Europe, and Asia-Pacific.